Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------------------------------|-------|-------|----------------- ...

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Joy Zhang - SVB Securities Sean Dodge - RBC Capital Markets Eric Martinuzzi - Lake Street Marc Wiesenberger - B. Riley Securities Jeff Garro - Piper Sandler Operator Good afternoon, everyone. Thank you for joining OptimizeRx's Second ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction ...

OptimizeRx Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers EXPERIENCE 20+ Leading Health Services and Financial Businesses `) Med Panel Will Febbo Chief Executive Officer Ed Stelmakh Ch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdictio ...

OptimizeRx Corporation (NASDAQ:OPRX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer & Chief Operating Officer Andrew D’Silva - Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Mark Wiesenberger - B. Riley Securities Max Michaelis - Lake Street Capital Markets Harvey Poppel - Poppel Operator Greetings. Welcome to Optim ...

PART I [Business](index=4&type=section&id=Item%201.%20Business) OptimizeRx is a digital health technology company connecting life sciences, healthcare providers, and patients to improve medication adherence [Overview](index=4&type=section&id=Item%201.%20Business_Overview) OptimizeRx operates a digital health platform integrated into point-of-care networks to enhance medication access and adherence for patients - The company's core business is a digital health platform that connects life sciences organizations, healthcare providers (HCPs), and patients at the point of care[20](index=20&type=chunk) - The platform reaches over **60% of U.S. HCPs** and is designed to help patients start and stay on their medications[20](index=20&type=chunk) - Operations are conducted through wholly-owned subsidiaries in the U.S. (Michigan, Delaware, New Jersey), Croatia, and Israel[21](index=21&type=chunk) [2021 Company Highlights](index=5&type=section&id=Item%201.%20Business_2021%20Company%20Highlights) In 2021, OptimizeRx achieved record net revenue of $61.3 million, returned to profitability, and expanded its platform capabilities 2021 Financial Highlights | Metric | 2021 Value | Change vs 2020 | | :--- | :--- | :--- | | Net Revenue | $61.3 million | +42% | | Q4 Net Revenue | $20.3 million | +24% | | Net Income | $0.4 million | From $2.2M Loss | | Cash Flow from Operations | $0.7 million | Positive | - Completed a public offering in February 2021, raising an additional **$70.7 million** in capital[24](index=24&type=chunk) - Launched a new Therapy Initiation Workflow to support specialty medications and an Evidence-Based Physician Engagement solution, which was recognized as an innovative product by PM 360 magazine[24](index=24&type=chunk) - The company was added to the S&P SmallCap 600 Index in October 2021[24](index=24&type=chunk) [Principal Solutions and Applications](index=5&type=section&id=Item%201.%20Business_Principal%20Solutions%20and%20Applications) The company's integrated platform offers solutions like financial messaging, patient engagement, and evidence-based physician engagement to support medication access - **Financial Messaging:** A virtual "Patient Support Center" within EMR/e-Prescribe systems for accessing co-pay coupons and vouchers[24](index=24&type=chunk) - **Patient Engagement:** Acquired capabilities from CareSpeak and RMDY Health provide interactive mobile messaging to improve medication adherence and care coordination[26](index=26&type=chunk) - **Evidence-Based Physician Engagement:** Uses AI and real-world data (RWD) to help HCPs identify qualified patients for specific therapies and monitor adherence[26](index=26&type=chunk) - **Therapy Initiation Workflow:** A digital solution to accelerate patient access to specialty medications by simplifying enrollment, benefits verification, and prior authorization[26](index=26&type=chunk) [Sales, Marketing, and Operations](index=6&type=section&id=Item%201.%20Business_Sales%2C%20Marketing%2C%20and%20Operations) The company shifted to enterprise sales, enhanced marketing, expanded its network, and migrated its core technology to AWS for improved scalability - Sales strategy is shifting from individual solutions to enterprise platform deals to increase revenue per customer and predictability[25](index=25&type=chunk) - Marketing strategy focused on strategic content resulted in a **10x increase** in engagement and higher brand visibility through organic channels[27](index=27&type=chunk) - Core technology platforms have been moved to Amazon Web Services (AWS) to support growth and improve efficiency[30](index=30&type=chunk) - The company is pursuing full Enterprise HITRUST Certification in 2022 to enhance security and compliance[31](index=31&type=chunk) [Competition, IP, and Employees](index=7&type=section&id=Item%201.%20Business_Competition%2C%20IP%2C%20and%20Employees) OptimizeRx competes in digital health, holds 3 patents, and employed 97 full-time staff as of December 31, 2021, with a focus on diversity - The primary direct competitor for the financial messaging solution is ConnectiveRx[34](index=34&type=chunk) - As of December 31, 2021, the company held **3 patents** and several pending applications, along with numerous trademarks like OPTIMIZERx, CareSpeak, and RMDY[35](index=35&type=chunk)[36](index=36&type=chunk) - As of December 31, 2021, the company had **82 full-time employees** in the U.S. and **15 full-time international employees** in Israel and Croatia[38](index=38&type=chunk) - In 2021, the company introduced a Diversity, Equity & Inclusion Committee and committed to the Parity Pledge, pledging to interview at least one qualified woman and underrepresented minority for every open role at the VP level or higher[39](index=39&type=chunk) [Risk Factors](index=9&type=section&id=Item%201A.%20Risk%20Factors) The company faces risks including historical losses, customer concentration, regulatory compliance, cybersecurity threats, and stock price volatility [Risks Relating to Our Business](index=9&type=section&id=Item%201A.%20Risk%20Factors_Risks%20Relating%20to%20Our%20Business) Business risks include historical losses, high customer and partner concentration, and exposure to complex healthcare regulatory compliance - While profitable in 2021, the company has a history of incurring losses due to investments in growth and acquisitions[43](index=43&type=chunk) - Revenues are concentrated in fewer than **50 customers**. In 2021, **one customer** represented over **10% of revenues**, compared to three such customers in 2020[50](index=50&type=chunk) - The company is reliant on its contracts with electronic prescribing platforms. In 2021, **53.9% of revenue** was generated through its largest partner, up from 52.7% in 2020[53](index=53&type=chunk) - The company is subject to complex healthcare regulations, including HIPAA and federal/state anti-kickback laws, which could impose significant compliance costs and penalties for violations[57](index=57&type=chunk)[59](index=59&type=chunk)[60](index=60&type=chunk) [Risks Related to IP, Technology, and Stock](index=15&type=section&id=Item%201A.%20Risk%20Factors_Risks%20Related%20to%20IP%2C%20Technology%2C%20and%20Stock) Risks include intellectual property protection, cybersecurity, system failures, stock price volatility, and anti-takeover provisions - The business depends on its ability to protect its intellectual property through patents and other measures; failure to do so could adversely affect its competitive position[74](index=74&type=chunk) - Cybersecurity incidents and IT system failures pose significant threats, potentially leading to data loss, business disruption, and reputational damage[76](index=76&type=chunk)[77](index=77&type=chunk) - The common stock (OPRX) has been thinly traded historically and its market price is likely to be highly volatile[79](index=79&type=chunk)[81](index=81&type=chunk) - The company has never paid dividends and does not expect to in the foreseeable future, meaning return on investment depends on stock price appreciation[82](index=82&type=chunk) [Unresolved Staff Comments](index=18&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments from the Securities and Exchange Commission - None[87](index=87&type=chunk) [Properties](index=18&type=section&id=Item%202.%20Properties) The company leases its principal executive offices in Michigan and an office in Croatia, with no owned real estate - The company does not own any real estate and leases all its office spaces[87](index=87&type=chunk) - Key leases include the headquarters in Rochester, MI (expires Nov 2023, with renewal option) and an office in Zagreb, Croatia (expires 2024)[88](index=88&type=chunk) [Legal Proceedings](index=18&type=section&id=Item%203.%20Legal%20Proceedings) The company reports no current legal proceedings - No current legal proceedings are reported[89](index=89&type=chunk) [Mine Safety Disclosures](index=18&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's business - Not applicable[90](index=90&type=chunk) [Information about Our Executive Officers](index=18&type=section&id=Item%204.1%20Information%20about%20Our%20Executive%20Officers) This section provides background and business experience for the company's executive officers as of February 24, 2022 Executive Officers as of Feb 24, 2022 | Name | Age | Position | | :--- | :--- | :--- | | William J. Febbo | 53 | Chief Executive Officer | | Stephen L. Silvestro | 44 | Chief Commercial Officer | | Marion Odence-Ford | 57 | General Counsel and Chief Compliance Officer | | Edward Stelmakh | 56 | Chief Financial Officer and Chief Operations Officer | | Todd Inman | 66 | Chief Technology Officer | PART II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=20&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq under "OPRX", with no anticipated cash dividends in the foreseeable future - Common stock is traded on the Nasdaq Capital Market under the symbol "OPRX"[100](index=100&type=chunk) - The company has never declared or paid cash dividends and does not plan to in the foreseeable future[101](index=101&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section details the company's 2021 financial performance, including 42% revenue growth, profitability, and liquidity, alongside strategic shifts [Overview and COVID-19 Update](index=21&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis_Overview%20and%20COVID-19%20Update) The company focuses on enterprise engagements and AI solutions, with COVID-19 increasing demand for digital health without adverse financial impact - Strategic focus is on shifting to enterprise-level engagements with recurring revenue streams to generate greater and more consistent revenues[105](index=105&type=chunk) - The COVID-19 pandemic increased demand for digital health solutions and did not negatively impact financial results in 2021[107](index=107&type=chunk)[110](index=110&type=chunk) [Key Performance Indicators](index=22&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis_Key%20Performance%20Indicators) Key performance indicators for 2021 show increased average revenue per top 20 pharma manufacturer and improved revenue per employee Key Performance Indicators (2021 vs. 2020) | KPI | 2021 | 2020 | | :--- | :--- | :--- | | Average revenue per top 20 pharma manufacturer | $2,484,557 | $1,945,650 | | Percent of top 20 pharma manufacturers as customers | 95% | 85% | | Percent of total revenue from top 20 pharma manufacturers | 77% | 76% | | Net revenue retention | 127% | 162% | | Revenue per average full-time employee | $729,674 | $614,378 | [Results of Operations (2021 vs. 2020)](index=24&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis_Results%20of%20Operations) In 2021, net revenue grew 42% to $61.3 million, gross margin improved to 58%, and the company achieved a net income of $0.4 million Annual Financial Performance | Metric | 2021 | 2020 | % Change | | :--- | :--- | :--- | :--- | | Net Revenue | $61.3M | $43.3M | +42% | | Gross Margin | $35.6M | $24.1M | +48% | | Gross Margin % | 58% | 56% | +2 p.p. | | Operating Expenses | $35.3M | $26.2M | +34% | | Net Income (Loss) | $0.4M | ($2.2M) | N/A | Operating Expense Breakdown (in millions) | Expense Category | 2021 | 2020 | | :--- | :--- | :--- | | Compensation Expense | $17.9 | $13.7 | | Stock-based Compensation | $5.5 | $3.2 | | Depreciation and Amortization | $2.1 | $2.1 | | Data | $1.0 | $0.2 | | Other Expenses | $8.8 | $7.0 | | **Total Operating Expense** | **$35.3** | **$26.2** | - The increase in operating expenses was primarily driven by higher compensation from adding **27 net new employees** and increased stock-based compensation due to a higher stock price and executive hiring[127](index=127&type=chunk)[129](index=129&type=chunk) [Quarterly Financial Information](index=27&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis_Quarterly%20Financial%20Information) Quarterly results for 2021 show consistent sequential revenue growth, culminating in a strong Q4 with over $20.3 million in revenue 2021 Quarterly Results (in thousands) | Quarter | Revenues | Gross Profit | Net Income (Loss) | Diluted EPS | | :--- | :--- | :--- | :--- | :--- | | Q1 | $11,229 | $6,125 | $(637) | $(0.04) | | Q2 | $13,626 | $8,045 | $352 | $0.02 | | Q3 | $16,125 | $9,077 | $40 | $0.00 | | Q4 | $20,313 | $12,392 | $623 | $0.03 | 2020 Quarterly Results (in thousands) | Quarter | Revenues | Gross Profit | Net Income (Loss) | Diluted EPS | | :--- | :--- | :--- | :--- | :--- | | Q1 | $7,585 | $4,343 | $(2,204) | $(0.15) | | Q2 | $8,783 | $5,144 | $(1,077) | $(0.07) | | Q3 | $10,519 | $6,014 | $(283) | $(0.02) | | Q4 | $16,426 | $8,604 | $1,357 | $0.08 | [Liquidity and Capital Resources](index=28&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis_Liquidity%20and%20Capital%20Resources) As of December 31, 2021, the company had strong liquidity with $105.7 million in working capital, primarily from a $70.7 million stock offering Cash Flow Summary (in millions) | Activity | 2021 | 2020 | | :--- | :--- | :--- | | Net cash from operating activities | $0.7 | $(6.3) | | Net cash used in investing activities | $(0.5) | $(0.1) | | Net cash from financing activities | $73.9 | $(1.9) | | **Net increase (decrease) in cash** | **$74.2** | **$(8.3)** | - Working capital increased to **$105.7 million** at year-end 2021 from $22.9 million at year-end 2020[143](index=143&type=chunk) - Financing activities in 2021 were driven by a **$70.7 million** net proceed from an underwritten stock offering and **$4.9 million** from option exercises, partially offset by a **$1.6 million** payment for contingent consideration from prior acquisitions[147](index=147&type=chunk) [Critical Accounting Policies](index=29&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis_Critical%20Accounting%20Policies) Critical accounting policies involve significant judgment in revenue recognition, cost of revenues, stock-based compensation, and intangible asset impairment - **Revenue Recognition:** Revenue is recognized over time as messages are delivered. Contracts are generally less than one year. Setup fees are recognized over the life of the initial program[152](index=152&type=chunk)[156](index=156&type=chunk) - **Cost of Revenues:** Primarily consists of revenue share paid to network partners, which is expensed at the time a message is distributed[159](index=159&type=chunk) - **Intangible Assets & Goodwill:** Intangibles are amortized on a straight-line basis. Goodwill and intangibles are evaluated for impairment when a triggering event occurs, and goodwill is tested annually. No impairment was recorded in 2020 or 2021[160](index=160&type=chunk)[162](index=162&type=chunk) - **Stock-based Compensation:** Fair value is estimated at the grant date. The Black-Scholes model is used for options, and for market-based restricted stock units (RSUs), a Monte Carlo simulation is used[163](index=163&type=chunk)[166](index=166&type=chunk) [Financial Statements and Supplementary Data](index=32&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the audited consolidated financial statements for 2021 and 2020, including the independent auditor's unqualified opinion [Report of Independent Registered Public Accounting Firm](index=33&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data_Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) UHY LLP issued an unqualified opinion on the financial statements and internal controls, identifying revenue recognition as a critical audit matter - The auditor, UHY LLP, provided an unqualified (clean) opinion on the financial statements and the effectiveness of internal controls over financial reporting[174](index=174&type=chunk) - Revenue recognition was identified as a Critical Audit Matter, involving complex judgments regarding performance obligations and timing[182](index=182&type=chunk)[183](index=183&type=chunk) [Consolidated Financial Statements](index=35&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data_Consolidated%20Financial%20Statements) Consolidated financial statements show total assets increased to $141.0 million in 2021, with cash rising to $84.7 million and a shift to $0.4 million net income Consolidated Balance Sheet Data (in thousands) | Account | Dec 31, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $84,682 | $10,517 | | Accounts receivable, net | $24,801 | $17,886 | | Total Current Assets | $115,113 | $32,859 | | Goodwill & Intangibles | $25,387 | $26,861 | | **Total Assets** | **$140,985** | **$60,328** | | **Liabilities & Equity** | | | | Total Current Liabilities | $9,369 | $10,028 | | Total Liabilities | $9,605 | $10,354 | | Total Stockholders' Equity | $131,380 | $49,974 | | **Total Liabilities & Equity** | **$140,985** | **$60,328** | Consolidated Statement of Operations Data (in thousands) | Account | Year Ended Dec 31, 2021 | Year Ended Dec 31, 2020 | | :--- | :--- | :--- | | Revenue | $61,293 | $43,313 | | Gross margin | $35,638 | $24,105 | | Total operating expenses | $35,277 | $26,241 | | Income (loss) from operations | $361 | $(2,135) | | **Net income (loss)** | **$378** | **$(2,207)** | | **Diluted EPS** | **$0.02** | **$(0.15)** | [Controls and Procedures](index=59&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management and the independent auditor concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2021 - Management concluded that both disclosure controls and procedures, and internal control over financial reporting, were effective as of December 31, 2021[320](index=320&type=chunk)[323](index=323&type=chunk) - The company's independent registered public accounting firm, UHY LLP, audited and issued an unqualified opinion on the effectiveness of the internal control over financial reporting[324](index=324&type=chunk) PART III [Directors, Executive Officers and Corporate Governance](index=61&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the 2022 proxy statement - Most information for this section is incorporated by reference from the 2022 Annual Meeting proxy statement[330](index=330&type=chunk) [Executive Compensation](index=61&type=section&id=Item%2011.%20Executive%20Compensation) Information on director and executive compensation is incorporated by reference from the 2022 proxy statement - All information for this section is incorporated by reference from the 2022 Annual Meeting proxy statement[331](index=331&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=62&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters.) This section details equity compensation plans as of December 31, 2021, with over 1.18 million securities outstanding and 2.13 million available Equity Compensation Plan Information as of December 31, 2021 | Plan Category | Securities to be Issued (Options & RSUs) | Securities Available for Future Issuance | | :--- | :--- | :--- | | Equity compensation plans approved by security holders | 1,183,750 | 2,132,791 | | Equity compensation plans not approved by security holders | - | - | | **Total** | **1,183,750** | **2,132,791** | [Certain Relationships and Related Transactions, and Director Independence](index=63&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the 2022 proxy statement - All information for this section is incorporated by reference from the 2022 Annual Meeting proxy statement[334](index=334&type=chunk) [Principal Accountant Fees and Services](index=63&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information on principal accountant fees and pre-approval policies is incorporated by reference from the 2022 proxy statement - All information for this section is incorporated by reference from the 2022 Annual Meeting proxy statement[334](index=334&type=chunk) PART IV [Exhibits and Financial Statements Schedules](index=64&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statements%20Schedules) This section lists financial statements and exhibits filed with the Form 10-K, including an index of all filed exhibits - This section provides an index of all financial statements and exhibits filed with the Form 10-K[336](index=336&type=chunk)[337](index=337&type=chunk) [Form 10-K Summary](index=65&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company reports no Form 10-K summary - None[340](index=340&type=chunk)

OptimizeRx Corporation. (NASDAQ:OPRX) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Andrew D’Silva - Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Marc Wiesenberger - B. Riley Securities Eric Martinuzzi - Lake Street Harvey Poppel - Poptech Capital LLP Operator Go ...

OptimizeRx Corporation (NASDAQ:OPRX) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants William Febbo – Chief Executive Officer Ed Stelmakh – Chief Financial Officer Stephen Silvestro – Chief Commercial Officer Andrew D’Silva – Senior Vice President of Corporate Finance Conference Call Participants Jared Haase – William Blair Sean Dodge – RBC Capital Markets Eric Martinuzzi – Lake Street Marc Wiesenberger – B. Riley Securities Operator Good afternoon, and thank you for joining ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to __________ (State or other jurisd ...